From the Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens (MHE, XC); Department of Family and Community Medicine, Penn State College of Medicine, Hershey (RL); Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles (DMT); Department of Health Services Research, Management and Policy, University of Florida, Gainesville (AGM); Departments of Public Health Sciences, and Anesthesiology and Perioperative Medicine, Penn State College of Medicine, Hershey (AEZ); Department of Family Medicine and Community Health, University of Wisconsin, Madison (BB, WJT); Department of Emergency Medicine, MedStar Washington Hospital Center, Washington, DC (KM, MG); Department of Family Medicine, Virginia Commonwealth University, Richmond (AK).
J Am Board Fam Med. 2021 Feb;34(Suppl):S127-S135. doi: 10.3122/jabfm.2021.S1.200464.
Develop and validate simple risk scores based on initial clinical data and no or minimal laboratory testing to predict mortality in hospitalized adults with COVID-19.
We gathered clinical and initial laboratory variables on consecutive inpatients with COVID-19 who had either died or been discharged alive at 6 US health centers. Logistic regression was used to develop a predictive model using no laboratory values (COVID-NoLab) and one adding tests available in many outpatient settings (COVID-SimpleLab). The models were converted to point scores and their accuracy evaluated in an internal validation group.
We identified 1340 adult inpatients with complete data for nonlaboratory parameters and 741 with complete data for white blood cell (WBC) count, differential, c-reactive protein (CRP), and serum creatinine. The COVID-NoLab risk score includes age, respiratory rate, and oxygen saturation and identified risk groups with 0.8%, 11.4%, and 40.4% mortality in the validation group (AUROCC = 0.803). The COVID-SimpleLab score includes age, respiratory rate, oxygen saturation, WBC, CRP, serum creatinine, and comorbid asthma and identified risk groups with 1.0%, 9.1%, and 29.3% mortality in the validation group (AUROCC = 0.833).
Because they use simple, readily available predictors, developed risk scores have potential applicability in the outpatient setting but require prospective validation before use.
根据初始临床数据和无或最少实验室检测结果,开发和验证简单的风险评分,以预测住院 COVID-19 成年患者的死亡率。
我们收集了来自美国 6 个医疗中心的连续住院 COVID-19 患者的临床和初始实验室变量,这些患者要么死亡,要么在 6 周时出院。使用逻辑回归建立一个不使用实验室值的预测模型(COVID-NoLab)和一个在许多门诊环境中可用的测试添加模型(COVID-SimpleLab)。将这些模型转换为点评分,并在内部验证组中评估其准确性。
我们确定了 1340 名具有完整非实验室参数数据的成年住院患者和 741 名具有完整白细胞(WBC)计数、差异、C 反应蛋白(CRP)和血清肌酐数据的患者。COVID-NoLab 风险评分包括年龄、呼吸频率和血氧饱和度,在验证组中识别出死亡率为 0.8%、11.4%和 40.4%的风险组(AUROCC=0.803)。COVID-SimpleLab 评分包括年龄、呼吸频率、血氧饱和度、WBC、CRP、血清肌酐和合并哮喘,在验证组中识别出死亡率为 1.0%、9.1%和 29.3%的风险组(AUROCC=0.833)。
由于这些风险评分使用了简单、易于获得的预测因素,因此具有在门诊环境中应用的潜力,但在使用前需要进行前瞻性验证。